Back to Search
DAVID BADESCH, MD
MD
Pulmonary Disease Physician
NPI: 1275623951IndividualAccepts Medicare
Specialties, Licenses & Credentials
Pulmonary Disease PhysicianPrimary
Internal Medicine — Pulmonary Disease
Code: 207RP1001X
28171(CO)
Hypertension Specialist Physician
Internal Medicine — Hypertension Specialist
Code: 207RH0005X
28171(CO)
Education
UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE
Class of 1983
Research & Publications (20)
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
PMID 18812445·Chest·2009
3-trial
Serotonin transporter polymorphisms in patients with portopulmonary hypertension.
PMID 19141529·Chest·2009
4-observational
Diagnosis and assessment of pulmonary arterial hypertension.
PMID 19555859·J Am Coll Cardiol·2009
6-review
End points and clinical trial design in pulmonary arterial hypertension.
PMID 19555863·J Am Coll Cardiol·2009
6-review
Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.
PMID 18625676·Chest·2008
4-observational
Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.
PMID 17565025·Chest·2007
6-review
Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.
PMID 17985403·J Rheumatol·2007
4-observational
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
PMID 15249494·Chest·2004
6-review
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
PMID 10733441·Ann Intern Med·2000
3-trial
Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study.
PMID 19375522·Contemp Clin Trials·2009
2-rct
ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association.
PMID 19389575·J Am Coll Cardiol·2009
6-review
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.
PMID 19218192·Am J Respir Crit Care Med·2009
4-observational
Pulmonary function testing in patients with pulmonary arterial hypertension.
PMID 19403296·Respir Med·2009
4-observational
Formulary management of recombinant factor VIIa at an academic medical center.
PMID 18477731·Ann Pharmacother·2008
8-other
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
PMID 18506008·Circulation·2008
4-observational
Surrogate and combined end points in pulmonary arterial hypertension.
PMID 18625754·Proc Am Thorac Soc·2008
6-review
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
PMID 18936500·Ann Intern Med·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 12605 E 16TH AVE
AURORA, CO 80045 - Phone
- (720) 848-0000
Quick Facts
- NPI
- 1275623951
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 43
- Publications
- 20
Are you this provider?
Claim Your Profile